A 5425

Drug Profile

A 5425

Alternative Names: A-5425

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Albireo
  • Developer Albireo Pharma
  • Class Skin disorder therapies
  • Mechanism of Action Neurokinin 1 antagonists; Neurokinin 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Psoriasis; Scars

Most Recent Events

  • 18 Jul 2016 Preclinical trials in Atopic dermatitis in Sweden (unspecified route)
  • 18 Jul 2016 Preclinical trials in Psoriasis in Sweden (unspecified route)
  • 18 Jul 2016 Preclinical trials in Scars (Prevention) in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top